Chris Viehbacher, Biogen CEO (Photographer: Scott Eells/Bloomberg via Getty Images)
February 15, 2023 02:28 PM EST
R&D
Pharma

Bio­gen CEO says com­pa­ny 'lost its way,' cuts $125M MS part­ner­ship amid de­clin­ing rev­enue

Katherine Lewin

News Reporter

Bio­gen has giv­en up on ore­labru­ti­nib, an BTK in­hibitor for the po­ten­tial treat­ment of mul­ti­ple scle­ro­sis, af­ter pay­ing $125 mil­lion for it in 2021. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times